B
DFTX

Bailard’s Definium Therapeutics DFTX Stock Holding History

Bailard’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,600
Closed -$94.8K – 845
2025
Q2 		$94.8K Hold
14,600
– – ﹤0.01% 741
2025
Q1 		$85.4K Hold
14,600
– – ﹤0.01% 722
2024
Q4 		$102K Sell
14,600
-9,500
-39% -$65.4K ﹤0.01% 716
2024
Q3 		$137K Hold
24,100
– – ﹤0.01% 721
2024
Q2 		$174K Hold
24,100
– – ﹤0.01% 695
2024
Q1 		$227K Buy
24,100
+6,800
+39% +$38.8K 0.01% 658
2023
Q4 		$63.3K Buy
+17,300
New +$52.1K ﹤0.01% 698

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bailard's DFTX Position: Q3 2025 in Review

Bailard sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 14,600 shares — an estimated $94.8K sold.

Bailard first reported a position in DFTX in Q4 2023 and held it in 7 quarters. The position peaked at $227K in Q1 2024. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • Bailard reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bailard sold 14,600 Definium Therapeutics shares in Q3 2025, an estimated $94.8K.
  • Bailard first reported a position in Definium Therapeutics in Q4 2023 and held it in 7 quarters.
  • Bailard's Definium Therapeutics position peaked at $227K in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Bailard's 13F filing for Q3 2025, filed 30 Oct 2025.